Bharat Biotech terminates agreement with Brazilian partners after graft allegations

This picture has been used for representational purpose. Pic/AFP

Bharat Biotech has terminated the Memorandum of Understanding entered with Precisa Medicamentos and Envixia Pharmaceuticals LL.C for its Covid-19 vaccine Covaxin for the Brazilian market.

The termination of the MoU came after the deal with the Brazilian government for the supply of 20 million doses of the vaccine landed in controversy and attracted investigation by authorities in that country.

Precisa Medicamentos is Bharat Biotech's partner in Brazil, providing assistance, guidance and support with regulatory submissions, licensure, distribution, insurance and conduct of phase III clinical trials, among others. "The Company has terminated the said MOU with immediate effect. Notwithstanding such termination, Bharat Biotech will continue to work diligently with ANVISA, the Brazilian drug regulatory body to complete the regulatory approval process for Covaxin," it said.

Bharat Biotech is pursuing approvals in various countries as per legal requirements applicable in each country, it said. Bharat Biotech signed a MoU with Precisa Medicamentos and Envixia Pharmaceuticals LL.C on November 20 for the purpose of introducing Covaxin in the territory of Brazil.

Also Read: Supreme Court directive on framing guidelines for compensation to Covid-19 victims under consultation: Govt

The global pricing of the vaccine has been set between USD 15-20 and accordingly, the jab was offered to the Government of Brazil at the rate of USD 15 per dose, Bharat Biotech said. It is further stated that the company has not received any advance payments from, nor has it supplied any vaccines to the Ministry of Health in Brazil, the company said.

The vaccine maker stressed that all its actions, including its global dealings, are done in accordance with local laws and the company employs and follows the highest standards of ethics, integrity and compliance at all times.

This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever.